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Objectives: Pancreatic exocrine insufficiency (PEI) is a common compli-
cation of chronic pancreatitis. However, little is known about the natural
course of PEI and the effect of pancreatic enzyme replacement therapy on
symptoms. The aim of this study was to evaluate the natural course and treat-
ment of PEI in a nationwide cohort of patients with chronic pancreatitis.
Methods: Patients with chronic pancreatitis were selected from the mul-
ticenter Dutch Chronic Pancreatitis Registry. Patients were classified in 3
groups: definite PEI, potential PEI, and no PEI. Definite PEI and no PEI
were compared regarding the course of disease, symptoms, treatment,
and quality of life.
Results: Nine hundred eighty-seven patients were included from 29 cen-
ters, of which 304 patients (31%) had definite PEI; 451 (46%), potentially
PEI; and 232 (24%), no PEI. Patients with definite PEI had significantly
moremalabsorption symptoms, a lower bodymass index, and aberrant def-
ecation. Lowered quality of lifewas not independently associated with PEI.
Of the PEI patients using pancreatic enzyme replacement therapy, 47% still
reported steatorrhea.
Conclusions: Pancreatic exocrine insufficiency is associated with malab-
sorption symptoms and a lower bodymass index. Some form of pancreatic en-
zyme replacement therapy is reasonably effective in alleviating malabsorption
symptoms, but improvement of treatment is needed.
Key Words:M-ANNHEIM criteria, pancreatic function loss, PERT,
undertreatment
(Pancreas 2020;49: 242–248)
C hronic pancreatitis (CP) is a progressive inflammatory dis-ease of the pancreas, which causes destruction and fibrosis
of functional pancreatic tissue and obstruction of the pancreatic
duct, which leads to exocrine and endocrine function loss of
the pancreas.
Pancreatic exocrine insufficiency (PEI) is reported in 21% to
94% of patients with CP, and its incidence increases with disease
duration.1–3 It is associated with steatorrhea, weight loss, and ab-
dominal discomfort. Because of malabsorption and maldigestion,
a deficit of fat-soluble vitamins is present in up to 65% of patients
with CP, resulting in clinical manifestations as osteoporosis, frac-
tures, immune deficiency, and infections.4–6
No malabsorption-related symptom can definitely prove the
presence of PEI, but in patients with these symptoms, the diagno-
sis of PEI can be made when the clinical presentation is combined
with exocrine pancreatic function tests.7 Current criterion stan-
dard for fat malabsorption is the coefficient of fat absorption test.
This test, however, is very invasive as the patient has to maintain a
strict diet for 5 days and has to collect the total amount of feces for
3 days. Therefore, the fecal elastase test (FE-1) is widely accepted
as a noninvasive pancreatic function test in clinical practice, despite
a lower accuracy.8
Pancreatic enzyme replacement therapy is the mainstay of
treatment in patients with PEI due to CP and reduces maldigestion
and malabsorption.7,8 Although pancreatic enzyme replacement
therapy is effective to reduce fecal fat excretion, the benefit for
clinical and nutritional outcomes remains equivocal.9,10 Recent
literature showed that 70% of the CP patients with PEI have
steatorrhea-related complaints despite pancreatic enzyme replace-
ment therapy, suggesting undertreatment of PEI.11
Although PEI is common in CP and enzyme replacement
therapy has been extensively studied, little is known about the nat-
ural course of exocrine insufficiency, the effect on well-being, and
the effect of treatment in clinical practice. Therefore, the aims of
this study were to evaluate the natural course of exocrine insuffi-
ciency in CP patients with respect to course of disease, symptoms,
and quality of life and to evaluate the effect of pancreatic enzyme
replacement therapy.
MATERIALS AND METHODS
We performed a cross-sectional analysis of data that were
collected prospectively as part of the Dutch Chronic Pancreati-
tis Registry (CARE).12 This study is written according the
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STROBE (Strengthening the Reporting of Observational Stud-
ies in Epidemiology) guidelines.13
CARE Database
The Dutch Chronic Pancreatitis Registry is a nationwide ob-
servational cohort study, coordinated by the Dutch Pancreatitis
Study Group, in 29 participating hospitals. In CARE, patients
with CP or recurrent acute pancreatitis (RAP) are included be-
tween 2011 and 2017. Data are being collected prospectively since
2011 by screening medical records and by at least yearly repeated
sending of validated questionnaires. All included patients had al-
ready an RAP or CP diagnosis before inclusion. Therefore, data
from before 2011, for example, the diagnosis date of CP, were col-
lected retrospectively by screening of medical records.12
Safety
This study was executed according the principles of the
Declaration of Helsinki and the human research laws in the
Netherlands. The Dutch Chronic Pancreatitis Registry has been
reviewed by the medical ethical committee of the University
Medical Center Utrecht and received an exempt status due to its
descriptive nature (ID: AvG/rc/10/05699; March 17, 2010). All
patients gave written informed consent for participation and per-
mission to use their medical records for this study.
Patient Selection
Patients who had definite CP according the M-ANNHEIM
criteria were included.14 We classified PEI in patients with CP in
3 groups: definite PEI, potential PEI, and no PEI. For the diagno-
sis of PEI, we used exocrine pancreatic function tests, steatorrhea
complaints, and usage of pancreatic enzyme replacement therapy.
Threshold of exocrine function test for diagnosis of exocrine
insufficiency was less than 200 μg/g for the fecal elastase-1
test, for the coefficient of fat absorption test greater than 5%
fat or greater than 7 g/24 h, and greater than 10% for the acid
steatocrit test.15–17
Definite PEI was defined as either (1) an abnormal exocrine
function test plus either steatorrhea or the use of pancreatic en-
zyme replacement or (2) no exocrine function test but steatorrhea
with a positive response on pancreatic enzyme replacement ther-
apy. Patients were considered having no PEI when having no ste-
atorrhea and no pancreatic enzyme replacement therapy, without a
documented abnormal exocrine function test or with a docu-
mented normal exocrine function test. All other patients were con-
sidered as having potential PEI. In this group, patients had (1)
steatorrhea or pancreatic enzyme replacement therapy without
an exocrine function test, (2) an abnormal exocrine function test
but no steatorrhea or pancreatic enzyme replacement therapy, or
(3) steatorrhea or pancreatic enzyme replacement therapy but with
a normal exocrine function test.
Data
Data were collected at inclusion in the registry by using a
questionnaire consisting of questions on demographics, intox-
ication (ie, alcohol, smoking), symptoms, defecation character-
istics, and medication usage. In addition, the validated Izbicki
pain questionnaire and validated Short-Form 36 (SF-36) for
quality of life were collected.18,19 Medical records were re-
viewed for data regarding pancreatic function, imaging, hospi-
talization, and treatment.
We compared patients with definite PEI and no PEI for
symptoms, course of disease, treatment, and quality of life at in-
clusion in the registry. Patients with potential PEI were only
presented in patient characteristics and in the regression analy-
sis for quality of life, but not included in the comparison anal-
ysis because the diagnosis of PEI was arguable in these patients.
Additionally, in patients with definite PEI, we examined the corre-
lation between usage of pancreatic enzyme replacement therapy
on one end, and patient-reported symptoms and dosage of en-
zymes on the other end. Thereby, we compared pain and quality
of life in patients with and without steatorrhea despite pancreatic
enzyme replacement therapy.
Statistical Analysis
Parametric data are expressed asmeanwith standard deviation
(SD), whereas nonparametric data are expressed as median with in-
terquartile range (IQR). Statistical comparisonwas performed using
χ2 test or Fisher exact test for categorical data and the Student t test
or Mann-Whitney U test for continuous data. P < 0.05 was consid-
ered to represent a significant statistical difference. Missing values
were not imputed.
Additionally, multivariate linear regression analyses were per-
formed to assess the independent predictors, including PEI and pan-
creatic enzyme replacement therapy, of physical andmental quality of
life. Variables were excluded through backward selection until only
statistically significant variables were selected in the final model.
RESULTS
Patient Characteristics
Patient characteristics per group are listed in Table 1. From
the 1360 patients prospectively included between 2011 and
2017 in CARE, a total of 987 patients had CP according the
M-ANNHEIM criteria; the remaining patients had RAP and were
excluded from the present study. Three hundred four of
987 patients (30.8%) had definite PEI; 451 (45.7%), potential
PEI; and 232 (23.5%), no PEI. The flowchart of patient selection
and group definition is depicted in Figure 1. Of the 987 included
patients, mean age (SD) was 58 (11.5) years, and 67% were men.
Four hundred eighty-seven patients (49%) underwent exocrine func-
tion testing, and 344 of them had an abnormal pancreatic function.
Alcohol was the most common etiology (51%) followed by idio-
pathic etiology (26%). One-third of the patients were active alcohol
users (33%), and a majority consisted of current smokers (60%).
Course of Disease
Median disease duration of CP was 83 months (IQR,
41–158 months) at inclusion in the registry. Disease duration
was significantly longer in patients with PEI, with a median
difference between definite PEI and no PEI of 26 months
(P < 0.001). Mean age at diagnosis was significantly lower
in patients with definite PEI compared with patients without
PEI (50 [SD, 13] years vs 53 [SD, 12] years; P = 0.01). Figure 2
visualizes the relation between the percentage of patients with
PEI and the duration of CP in a 1 − survival plot. According this
figure, the percentage of PEI is steadily increasing from 20% after
5 years of CP to 70% after 20 years of CP. Diabetes mellitus was
present in 50% of patients with PEI compared with 18% in pa-
tients without PEI (P < 0.001). Previous surgery was associated
with the presence of PEI, whereas previous endoscopy was not as-
sociated (P < 0.001 and P = 0.709, respectively) (Table 1).
Symptoms and Treatment of PEI
Pancreatic exocrine insufficiency was inversely associated
with bodymass index (BMI); significantly more PEI patients were
classified as underweight compared with CP patients without PEI
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TABLE 1. Patients Characteristics
All CP
(n = 987, 100%)
PEI
(n = 304, 30.8%)
No PEI
(n = 232, 23.5%)
Potential PEI
(n = 451, 45.7%)
P (PEI vs
No PEI)
Age, mean (SD), y 58 (11.5) 58 (11.0) 58 (11.7) 58 (11.7) 0.923
Duration of CP, median (IQR), mo 83 (41–158) 97 (50–181) 64 (34–114) 94 (47–175) <0.001
Duration symptoms CP, median (IQR), y 91 (47–170) 119 (58–200) 71 (39–130) 85 (41–159) <0.001
Sex, male, n (%) 659/987 (66.8) 203/304 (66.8) 155/232 (66.8) 301/451 (66.7) 0.993
BMI, median (IQR), kg/m2 23.4 (21.0–26.1) 22.8 (20.2–25.0) 23.8 (21.5–26.9) 23.5 (21.0–26.6) <0.001
Etiology CP, n (%) 0.796
Alcohol 435/854 (50.9) 138/270 (51.1) 101/203 (49.8) 196/381 (51.4)
Idiopathic 219/854 (25.7) 70/270 (25.9) 50/203 (24.6) 99/381 (26.0)
Other 200/854 (23.4) 62/270 (23.0) 52/203 (25.6) 86/381 (22.6)
Smoking, n (%) 0.407
Never 117/981 (11.9) 35/304 (11.5) 25/231 (10.8) 57/446 (12.8)
Past 273/981 (27.8) 80/304 (26.3) 73/231 (31.6) 120/446 (26.9)
Current 591/981 (60.2) 189/304 (62.2) 133/231 (57.6) 269/446 (60.3)
Pack-years, median (IQR), y 27.0 (10.0–40.0) 27.0 (8.9–40.0) 24.4 (8.4–37.5) 28.5 (10.3–41.0)
Alcohol, n (%) 0.784
Never 122/981 (12.4) 31/304 (10.2) 27/232 (11.6) 64/445 (14.4)
Past 534/981 (54.4) 172/304 (56.6) 125/232 (53.9) 237/445 (53.3)
Current 325/981 (33.1) 101/304 (33.2) 80/232 (34.5) 144/445 (32.4)
Alcohol, units/d, median (IQR) 5 (1–10) 5 (2–10) 5 (2–10) 4 (1–8)
Diabetes mellitus, n (%) 371/987 (37.6) 152/304 (50.0) 43/232 (18.5) 176/451 (39.0) <0.001
Previous endoscopy, n (%) 262/987 (26.5) 86/304 (28.3) 60/232 (25.9) 116/451 (25.7) 0.709
Previous surgery, n (%) 304/987 (30.8) 115/304 (37.8) 52/232 (22.4) 137/451 (30.4) <0.001
FIGURE 1. Flowchart of patient enrollment and group selection. Definite PEI: positive exocrine function test plus either steatorrhea or the use
of pancreatic enzyme replacement (columns 1 and 2) or no exocrine function test but steatorrhea with a positive response on pancreatic
enzyme replacement therapy (column 3). Definitely no PEI: having no steatorrhea and no pancreatic enzyme replacement therapy, with a
documented abnormal exocrine function test (column 1) or without a documented normal exocrine function test (column 2). Potential PEI:
steatorrhea or pancreatic enzyme replacement therapy without an exocrine function test (columns 1 and 2), an abnormal exocrine function
test but no steatorrhea or pancreatic enzyme replacement therapy (column 3), or steatorrhea or pancreatic enzyme replacement therapy
but with a normal exocrine function test (columns 4 and 5). ExoTestPos, exocrine pancreatic function test positive; ExoTestNeg, exocrine
pancreatic function test negative; IPMN, intraductal papillary mucinous neoplasm; PERT, pancreatic enzyme replacement therapy.
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(12% vs 3%, P < 0.001). Both PEI and no PEI groups had a high
percentage of unintended weight loss of 38% and 34%, respec-
tively. Malabsorption-related symptoms such as nausea after a
meal, pain after a meal, and steatorrhea were significantly associ-
ated with PEI, but were also present in some proportion of CP pa-
tients without PEI. Defecation frequency was higher and of looser
consistency in patients with definite PEI. The Izbicki pain score at
present cross-sectional analysis was higher in the definite PEI
group with a mean score of 45 points (SD, 30) compared with
35 (SD, 27) in the no PEI group (P < 0.001).
Eighty-eight percent of patients with definite PEI were
treated with pancreatic enzyme replacement therapy with a
median dosage of 100,000 units of lipase a day (IQR,
75,000–175,000); 56% of patients with PEI used a proton
pump inhibitor (PPI). Only 31% of all patients with PEI were
referred to a dietitian. Detailed information about symptoms
and treatment of PEI is listed in Table 2.
Quality of Life
Overall, patients had a mean score of 41.9 (SD, 11.3) for the
physical component and 46.0 (SD, 12.1) for the mental compo-
nent on the quality-of-life SF-36 questionnaire compared with
the standard mean score of 50 (SD, 10) of the reference Dutch
population. The physical component was significantly lower in
patients with PEI compared with patients without PEI (40.5 vs
44.0, P < 0.001; Table 2). However, in the multivariate analysis,
PEI was not associated with a lower quality of life. Predictors
of a lower physical quality of life were younger age, female
sex, smoking, and a higher Izbicki pain score. Predictors for a
lower mental quality of life were younger age, alcoholic etiology
of CP, and a higher Izbicki pain score (Supplemental Table 1,
http://links.lww.com/MPA/A767). When excluding the Izbicki
pain score in the multivariate regression analysis, PEI was sig-
nificantly associated with a lower physical quality of life, sug-
gesting that patients with PEI have more complaints and
therefore a lower quality of life (Supplemental Table 2, http://
links.lww.com/MPA/A767).
Pancreatic Enzyme Replacement Therapy in
Definite PEI Patients
Symptoms for PEI patients with and without pancreatic en-
zyme replacement therapy are listed in Table 3. Pancreatic en-
zymes were used by the vast majority of patients with definite
PEI (88%). Nevertheless, 47% of patients receiving pancreatic en-
zyme replacement still reported steatorrhea. Furthermore, unin-
tended weight loss, postprandial nausea, and pain directly after
meal still were present in a considerable proportion of those pa-
tients (36%, 26%, and 42%, respectively). The relation between
malabsorption-related complaints and dosage of pancreatic enzyme
replacement therapy is presented in Supplemental Figure 1, http://
links.lww.com/MPA/A767. No correlation was seen between the
malabsorption-related complaints (steatorrhea, weight loss, post-
prandial nausea, postprandial pain, appetite) and dosage.
In patients without pancreatic enzyme replacement therapy,
prevalence of symptoms of unintentional weight loss, steatorrhea,
or nausea after meal was higher than in patients with pancreatic
enzyme replacement therapy. Stool was often loose in nonusers
(75%) compared with users of pancreatic enzyme replacement
therapy (54%, P = 0.038). Pain scores and quality of life were
comparable between pancreatic enzyme replacement therapy
users and nonusers. Also, in the multivariate regression analysis,
pancreatic enzyme replacement therapy was not associated with
quality of life (Supplemental Table 3, http://links.lww.com/
MPA/A767).
In patients with pancreatic enzyme replacement therapy and
without steatorrhea (adequate treatment), the Izbicki pain score
was lower compared with patients with steatorrhea despite pancre-
atic enzyme replacement therapy (nonadequate treatment) (−13.3
points, P = 0.002). Thereby, quality of lifewas significantly higher
in patients without steatorrhea. Mean units of lipase per day were
the same between both groups (Table 4).
DISCUSSION
In this representative Dutch multicenter CP registry, approx-
imately 1 in 3 patients had definite PEI after a median CP duration
of 6.9 years. Prevalence of PEI steadily increased with disease
FIGURE 2. Percentage of PEI after the onset of chronic pancreatitis. Correlation between duration CP and percentage PEI shown in a
1 − survival plot.
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duration to more than 80% after 30 years. Patients with PEI had
significantly more malabsorption-related symptoms, a lower
BMI, and more frequent defecation and of loose consistency de-
spite pancreatic enzyme replacement therapy in the vast majority
of these patients. Patients with PEI had a lower physical quality
of life, but PEI was not one of the predictors of a lower quality
of life. Potentially, PEI patients have a more advanced stage of dis-
ease with more complaints, including pain, and therefore a lower
quality of life. Pancreatic enzyme replacement therapy in patients
with definite PEI was associated with a reduction of malabsorp-
tion complaints and defecation problems. Surprisingly, 47% of pa-
tients who used pancreatic enzyme replacement therapy still had
malabsorption-associated complaints, and no correlation between
dosage andmalabsorption complaints was seen. However, the me-
dian dosage of 100,000 units a day was quite low compared with
current clinical guidelines.8 These patients had more pain and a
lower quality of life compared with patients with adequate pancre-
atic enzyme replacement therapy.
Previous publications report that 63% and 71% to 87% of pa-
tients with CP had PEI 5 years after diagnosis of CP.1,3 Our per-
centage of 31% PEI is much lower, which is most likely due to
the differences in establishing the diagnosis of CP and PEI. In
the present study, criteria for diagnosis of PEI were much stricter
compared with the criteria of Dumasy et al1 and Ammann et al,3
as we diagnosed PEI only when a patient had malabsorption com-
plaints and additionally an abnormal pancreatic function test or
positive effect on pancreatic enzyme replacement therapy. The in-
crease of PEI with disease duration that was present in our cohort
has also been demonstrated by Dumasy et al.1 In that study, PEI
increased from 63% within 5 years after diagnosis to 95% after
10 years of CP diagnosis.1 In our study, the percentage was much
lower, also most likely due to our strict PEI diagnosis criteria (20%
after 5 years to 43% after 10 years of CP diagnosis).
Patients with CP demonstrate an overall reduction in quality
of life for both physical and mental components, which is similar
to the quality of life of patients with other chronic diseases.20
In our study, PEI in CP was not associated with a more im-
paired quality of life. Although pancreatic enzyme replacement
therapy improved malabsorption-related symptoms such as steat-
orrhea and nausea, it was vice versa not associated with a higher
quality of life. A recent systematic review on efficacy of pancre-
atic enzyme replacement therapy has shown that pancreatic en-
zyme replacement therapy improves gastrointestinal symptoms
and quality of life.10 Also another cohort showed that pancreatic
enzyme replacement therapy was associated with symptom relief
and improvement in quality of life.21 We are not certain why the
use of pancreatic enzymes was not associated with an increased
quality of life. However, a logical explanation may be that
TABLE 2. Symptoms and Treatment
All CP
(n = 987, 100%)
PEI
(n = 304, 30.8%)
No PEI
(n = 232, 23.5%)
P (PEI vs
No PEI)
BMI classification (WHO), kg/m2, n (%) <0.001
Underweight (<18.5) 75/983 (7.6) 35/302 (11.6) 7/232 (3.0)
Normal range (18.5–24.9) 582/983 (59.2) 191/302 (63.2) 138/232 (59.5)
Overweight (25.0–29.9) 253/983 (25.7) 64/302 (21.2) 64/232 (27.6)
Obese (>30) 73/983 (7.4) 12/302 (4.0) 23/232 (9.9)
Unintended weight loss, n (%) 350/975 (35.9) 116/302 (38.2) 79/230 (34.3) 0.335
Nausea after meal, n (%) 153/680 (22.5) 70/242 (28.9) 33/204 (16.2) 0.001
Pain after meal, n (%) 242/680 (35.6) 106/242 (43.8) 54/204 (26.5) <0.001
No appetite, n (%) 143/679 (21.1) 55/242 (22.7) 36/204 (17.6) 0.185
Steatorrhea, n (%) 207/681 (30.4) 135/244 (55.3) 0/232 (0.0) <0.001
Defecation frequency, median (IQR), times a day 2 (1–2) 2 (1–3) 1 (1–2) <0.001
Defecation consistency, n (%) <0.001
Liquid 46/637 (7.2) 17/225 (7.6) 12/195 (6.2)
Loose 219/637 (34.4) 113/225 (50.2) 34/195 (17.4)
Normal 357/637 (56.0) 90/225 (40.0) 146/195 (74.9)
Hard 15/637 (2.4) 5/225 (2.2) 3/195 (1.5)
Defecation color, n (%) <0.001
Black 21/651 (3.2) 9/234 (3.8) 2/194 (1.0)
Brown 549/651 (84.3) 175/234 (74.8) 185/194 (95.4)
White 81/651 (12.4) 50/234 (21.4) 7/194 (3.6)
Izbicki pain score, mean (SD), 0–100 40.8 (28.5) 45.1 (30.0) 34.6 (26.6) <0.001
Quality of life (SF-36), mean (SD)
Physical component 41.9 (11.3) 40.5 (11.0) 44.0 (11.2) <0.001
Mental component 46.0 (12.1) 45.5 (12.4) 46.8 (11.4) 0.220
Medical treatment
PERT, n (%) 471/987 (47.7) 266/304 (87.5) 0/232 (0.0) <0.001
Dosage PERT, median (IQR) 100,000 (75,000–150,000) 100,000 (75,000–175,000) 0 (0–0)
PPI, n (%) 463/987 (46.9) 171/304 (56.3) 85/232 (36.6) <0.001
Dietitian referral, n (%) 245/979 (25.0) 93/303 (30.7) 33/230 (14.3) <0.001
PERT indicates pancreatic enzyme replacement therapy; WHO, World Health Organization.
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symptoms such as pain had a much higher impact on quality of
life, exemplified by the fact that a higher Izbicki pain score was
strongly associated with a lower quality of life. We deliberately
used the SF-36 questionnaire to measure quality of life, being a
general questionnaire that has been validated for many diseases
and used extensively for CP as well.22,23 This allows for reliable
comparison between our cohort and previous cohorts. Thereby,
no real specific quality-of-life questionnaire exists, except the Eu-
ropean Organisation for Research and Treatment of Cancer Qual-
ity of Life Questionnaire C30 with Pancreatic Cancer 28 module,
which is a much longer questionnaire and is used much less fre-
quently.24 Moreover, it has actually been adapted from the PAN-26
which was developed for pancreatic cancer, with the addition of
2 questions about alcohol use.
Notably, almost half of patients with pancreatic enzyme
replacement therapy still reported steatorrhea. The high per-
centage of steatorrhea in pancreatic enzyme replacement
therapy users was also mentioned by Sikkens et al.11 In their
survey about PEI in patients with CP, 70% of the patients reported
steatorrhea-related complaints despite pancreatic enzyme replace-
ment therapy.11 This could possibly be related to insufficient dos-
ing of pancreatic enzymes, but in our cohort, no relation was seen
between dosage of pancreatic enzyme replacement therapy and
malabsorption-related complaints (Supplemental Fig. 1, http://
links.lww.com/MPA/A767). Perhaps, steatorrhea despite prescribed
treatment dosage is caused by a low compliance of the patient or an
inadequate administration of enzymes. Although it is stated in the
United European Gastroenterology Guidelines for CP that dietitian
referral and administration of PPI are advised to improve com-
plaints of PEI, only 30% of the patientswere referred to a dietitian,
and 56% had a PPI as comedication with their pancreatic enzyme
replacement therapy.8 Thus, in current clinical practice, patients
with PEI are probably not optimally educated about diet and en-
zyme use and not treated according to the guidelines. The efficacy
TABLE 3. Symptoms in Patients With PEI
All PEI
(n = 304, 100%)
PERT
(n = 266, 87.5%)
No PERT
(n = 38, 12.5%) P (PERT vs No PERT)
BMI, median (IQR), kg/m2 22.8 (20.2–25.0) 23.5 (20.4–25.1) 22.6 (20.2–25.0) 0.604
Unintended weight loss, n (%) 116/302 (38.2) 95/264 (36.0) 21/38 (55.3) 0.022
Nausea after meal, n (%) 70/242 (28.9) 54/205 (26.3) 16/37 (43.2) 0.037
Pain after meal, n (%) 106/242 (43.8) 86/205 (42.0) 20/37 (54.1) 0.172
No appetite, n (%) 55/242 (22.7) 47/205 (22.9) 8/37 (21.6) 0.862
Steatorrhea, n (%) 135/244 (55.3) 97/206 (47.1) 38/38 (100) <0.001
Defecation frequency, median (IQR), times a day 2 (1–3) 2 (1–2.5) 2 (1–3) 0.193
Defecation consistency, n (%) 0.038
Liquid 17/225 (7.6) 12/192 (6.3) 5/33 (15.2)
Loose 113/225 (50.2) 92/192 (47.9) 21/33 (63.6)
Normal 90/225 (40.0) 83/192 (43.2) 7/33 (21.2)
Hard 5/225 (2.2) 5/192 (2.6) 0/33 (0.0)
Defecation color, n (%) 0.767
Black 9/234 (3.8) 8/199 (4.0) 1/35 (2.9)
Brown 175/234 (74.8) 150/199 (75.4) 25/35 (71.4)
White 50/234 (21.4) 41/199 (20.6) 9/35 (25.7)
Izbicki pain score, mean (IQR), 0–100 45.1 (30.0) 44.0 (29.8) 53.2 (30.5) 0.094
Quality of life (SF-36), mean (SD)
Physical component 40.5 (11.0) 40.6 (11.0) 39.9 (11.6) 0.711
Mental component 45.5 (12.4) 45.6 (12.5) 44.9 (11.3) 0.729
PERT indicates pancreatic enzyme replacement therapy.
TABLE 4. Outcomes of Adequate PERT Treatment
All PERT*
(n = 206, 100%)
PERT With Steatorrhea
(n = 97, 47%)
PERT Without Steatorrhea
(n = 109, 53%)
P (Steatorrhea vs
No Steatorrhea)
PERT dosage, median (IQR) 100,000
(75,000–175,000)
106,250 (75,000–175,000) 106,250 (75,000–159,375) 0.904
Izbicki pain score, mean (SD), 0–100 44.0 (29.8) 50.9 (28.7) 37.6 (29.6) 0.002
SF-36: physical component summary,
mean (SD)
40.6 (11.0) 38.7 (10.9) 43.5 (10.0) 0.001
SF-36: mental component summary,
mean (SD)
45.6 (12.5) 43.1 (13.1) 48.2 (11.2) 0.003
*Steatorrhea data were missing in 60 patients.
PERT indicates pancreatic enzyme replacement therapy.
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of pancreatic enzyme replacement therapy in clinical practice has
to be frequently monitored for each patient individually and tai-
lored to complaints, the diet, and remnant pancreatic function.
Thereby a patient has to be educated about diet and enzyme ad-
ministration to aid in compliance on treatment and to reduce
steatorrhea complaints.
To avoid contamination between the groups of patients with
definite PEI and without PEI, we aimed to define strict criteria to
divide these groups, resulting in a relatively large group of patients
with no proven PEI, which was considered as having potential
PEI. However, this selection may have introduced selection bias
by allocating patients with mild PEI in the potential PEI group.
Hence, this studymay have overestimated the differences between
patients with definite PEI and without PEI, because the PEI group
potentially missed the mild PEI patients. A second limitation of
this study is the cross-sectional analysis. This makes it impossible
to determine cause and effect. For example, malabsorption-related
symptoms are the reason to start pancreatic enzyme replacement
therapy but are also the outcome to measure effect of pancreatic
enzyme replacement therapy. Therefore, determining the associa-
tion between malabsorption-related symptoms and pancreatic en-
zyme replacement therapy dosage is difficult. All patients are
included prospectively, but they had already a diagnosis of RAP
of CP at inclusion. Therefore, we had to collect data retrospec-
tively from before inclusion, which may have introduced recall
bias. However, this was a small amount of the data and was only
collected by screening medical records. Therefore, the influence
of recall bias in this study is very limited.
Further research should focus on the diagnosis of PEI by de-
veloping an accurate tool, or a combination of tools, to evaluate
PEI. Also, more research is needed on how to improve the efficacy
of pancreatic enzyme replacement therapy because a high percent-
age of patients using these medications still suffer from
malabsorption-related symptoms. Our study suggests that just in-
creasing the dosage without appropriate dietary counseling and
use of necessary adjuvant therapy (eg, PPI) does not lead to fewer
malabsorption-related symptoms.
Physicians should frequently measure symptoms and test
pancreatic function to diagnose PEI in the CP population and offer
patients optimal treatment using an adequate dosage of pancreatic
enzymes and counseling. To achieve optimal result of treatment in
PEI patients, comedication, dietary referral, and frequent counsel-
ing to evaluate the effect of therapy are needed.
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